High-dose intravenous human immunoglobulin in polymyositis resistant to treatment

S. Jann; S. Beretta; M. Moggio; L. Adobbati; G. Pellegrini

High-dose intravenous human immunoglobulin in polymyositis resistant to treatment

S. Jann, S. Beretta, M. Moggio, L. Adobbati, G. Pellegrini

Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico

Research output: Contribution to journal › Article › peer-review

Abstract

Two patients were treated with treatment-resistant polymyositis with intravenous immunoglobulin over four days at a dose of 0.4 g/kg/day. Clinical recovery followed within two months. Serum creatine kinase (CK) activity decreased to normal, and a clear improvement in muscle strength was observed. One patient showed neither clinical relapses nor increase in serum CK activity after 20 months. The other showed a mild increase in serum CK activity after 24 months and was successfully retreated with intravenous immunoglobulin. There were no significant adverse side effects.

Original language	English
Pages (from-to)	60-62
Number of pages	3
Journal	Journal of Neurology, Neurosurgery and Psychiatry
Volume	55
Issue number	1
Publication status	Published - 1992

ASJC Scopus subject areas

Psychiatry and Mental health
Neuroscience(all)
Neuropsychology and Physiological Psychology

Fingerprint Dive into the research topics of 'High-dose intravenous human immunoglobulin in polymyositis resistant to treatment'. Together they form a unique fingerprint.

Cite this

@article{068bcb5c2fc1450e97aff078a169b089,

title = "High-dose intravenous human immunoglobulin in polymyositis resistant to treatment",

abstract = "Two patients were treated with treatment-resistant polymyositis with intravenous immunoglobulin over four days at a dose of 0.4 g/kg/day. Clinical recovery followed within two months. Serum creatine kinase (CK) activity decreased to normal, and a clear improvement in muscle strength was observed. One patient showed neither clinical relapses nor increase in serum CK activity after 20 months. The other showed a mild increase in serum CK activity after 24 months and was successfully retreated with intravenous immunoglobulin. There were no significant adverse side effects.",

author = "S. Jann and S. Beretta and M. Moggio and L. Adobbati and G. Pellegrini",

year = "1992",

language = "English",

volume = "55",

pages = "60--62",

journal = "Journal of Neurology, Neurosurgery and Psychiatry",

issn = "0022-3050",

publisher = "BMJ Publishing Group",

number = "1",

}

TY - JOUR

T1 - High-dose intravenous human immunoglobulin in polymyositis resistant to treatment

AU - Jann, S.

AU - Beretta, S.

AU - Moggio, M.

AU - Adobbati, L.

AU - Pellegrini, G.

PY - 1992

Y1 - 1992

N2 - Two patients were treated with treatment-resistant polymyositis with intravenous immunoglobulin over four days at a dose of 0.4 g/kg/day. Clinical recovery followed within two months. Serum creatine kinase (CK) activity decreased to normal, and a clear improvement in muscle strength was observed. One patient showed neither clinical relapses nor increase in serum CK activity after 20 months. The other showed a mild increase in serum CK activity after 24 months and was successfully retreated with intravenous immunoglobulin. There were no significant adverse side effects.

AB - Two patients were treated with treatment-resistant polymyositis with intravenous immunoglobulin over four days at a dose of 0.4 g/kg/day. Clinical recovery followed within two months. Serum creatine kinase (CK) activity decreased to normal, and a clear improvement in muscle strength was observed. One patient showed neither clinical relapses nor increase in serum CK activity after 20 months. The other showed a mild increase in serum CK activity after 24 months and was successfully retreated with intravenous immunoglobulin. There were no significant adverse side effects.

UR - http://www.scopus.com/inward/record.url?scp=0026503279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026503279&partnerID=8YFLogxK

M3 - Article

C2 - 1372349

AN - SCOPUS:0026503279

VL - 55

SP - 60

EP - 62

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 0022-3050

IS - 1

ER -